Fundraise

Ansa raises $71.5M Series C to scale guaranteed DNA synthesis

What's the deal? Ansa Biotechnologies has closed an oversubscribed $71.5 million Series C led by Blue Water Life ScienceDealroom has a profile for this one. Try Dealroom → Advisors, bringing its total funding to $211 million. The round drew new backers Illumina VenturesDealroom has a profile for this one. Try Dealroom →, BEVCDealroom has a profile for this one. Try Dealroom →, Lightscape PartnersDealroom has a profile for this one. Try Dealroom →, and Agent CapitalDealroom has a profile for this one. Try Dealroom →, alongside existing investors Cerberus VenturesDealroom has a profile for this one. Try Dealroom →, Fall Line CapitalDealroom has a profile for this one. Try Dealroom →, Dauntless VenturesDealroom has a profile for this one. Try Dealroom →, and Altitude Life Science VenturesDealroom has a profile for this one. Try Dealroom →.

What's the endgame? Ansa uses a proprietary enzymatic DNA synthesis platform to make long, complex synthetic DNA that conventional methods struggle to produce. It offers sequence-perfect clonal DNA up to 50 kilobases and an on-time delivery guarantee: miss the ship date, and the order is free.

The money will fund expanded capabilities and scaled operations to meet rising customer demand across drug discovery, cell and gene therapies, vaccines, and agrigenomics.

Why now? AI-enabled drug discovery and biological design are driving demand for longer, more complex DNA sequences. Conventional synthesis is limited by sequence length and manufacturing reliability, which can block researchers from turning computational designs into physical DNA to validate AI models.

The raise follows a $54.4 million Series B in October 2025, after which the company says it has quadrupled manufacturing capacity.

The round also reshapes Ansa's board. Illumina Ventures founding partner Nick Naclerio, life science tools executive Brad Crutchfield, and Blue Water chief investment officer Nate Cornell have joined; Crutchfield will serve as an independent director.

What they're saying: "The full potential of AI-enabled biology depends on the ability to build and test what computational models design," said Naclerio. "That combination of technical capability and commercial execution is why we invested."

What could go wrong? Competition is intensifying. In October 2026, Azenta's GENEWIZDealroom has a profile for this one. Try Dealroom → licensed Elegen's cell-free DNA technology and acquired SynPlexityDealroom has a profile for this one. Try Dealroom → to strengthen gene-synthesis capabilities. The key test is whether Ansa can convert its capacity and reliability claims into sustained demand.

The signal: Investors are betting on differentiated DNA-synthesis services as AI pushes biology toward designs that older methods cannot reliably build. Ansa's pitch — long sequences plus a delivery guarantee — is the bet that reliability, not just capability, wins customers.

Read more: markets.financialcontent.com

Image credit: "Joey Holder" by Rosa Menkman, licensed under CC BY 2.0

More top stories